Haem: Chronic Lymphocytic Leukaemia: Free MSRA Podcast

🎙️ Deep Dive: Chronic Lymphocytic Leukaemia (CLL) – Your Shortcut to Mastery 🧬🩸🧠Feeling buried under CLL revision notes? 📚 Like those lymphocytes are multiplying faster than your brain can keep up? 😅 Don’t worry — we’ve broken it all down for you in this focused, high-yield revision episode, perfect for MSRA prep or clinical practice.🔍 What You’ll Learn in This Deep Dive:✅ Definition & Overview→ CLL = slow-growing B-cell cancer→ Accumulation of monoclonal, functionally immature lymphocytes→ Most common leukaemia in adults (accounts for ~25% of cases)✅ Aetiology & Risk Factors→ Cause unknown: combination of genetic predisposition (e.g. TP53 mutations) & possible environmental triggers (e.g. pesticides)→ ⬆️ Risk with age, male sex, family history, and specific gene mutations→ Average diagnosis age: 70 years✅ Pathophysiology→ Clonal expansion of abnormal B-cells→ Immune dysfunction due to impaired antibody production→ Bone marrow crowding → ⬇️ RBCs, platelets → anaemia, thrombocytopenia✅ Presentation & Symptoms→ Often asymptomatic, found on routine blood test→ If symptomatic:Fatigue, weight loss, night sweatsLymphadenopathy (rubbery, symmetrical)Splenomegaly, recurrent infections, bruising, petechiae✅ Investigations→ 📈 Lymphocytosis ≥5,000/μL for 3+ months→ Flow cytometry = confirms monoclonal B-cells→ Blood smear: small lymphocytes + smudge cells 🧫→ Cytogenetic testing: esp. TP53 mutation→ Imaging for bulky nodes/splenomegaly (not routine for staging)✅ Staging (Binet system – Europe/UK)→ Stage A: <3 lymphoid areas, Hb ≥10g/dL, platelets ≥100→ Stage B: ≥3 areas, normal Hb/platelets→ Stage C: Hb <10g/dL and/or platelets <100🔑 Mnemonics: A = Almost normal, B = Burden of nodes, C = Cytopenias✅ Management→ 🎯 Watchful waiting if asymptomatic→ Start treatment only if symptomatic, progressive disease, or advanced stage→ Treatment options:Targeted therapy: Venetoclax, Ibrutinib, AcalabrutinibChemo-immunotherapy: FCR (Fludarabine, Cyclophosphamide, Rituximab)Monoclonal antibodies: Rituximab, Obinutuzumab🌱 Allogeneic stem cell transplant (for high-risk, relapsed cases)✅ Complications→ 📉 Immunosuppression → frequent infections→ 🩸 Autoimmune haemolytic anaemia, ITP→ ⚠️ Richter’s transformation: CLL → aggressive lymphoma (5–10% risk)→ ⬆️ Risk of secondary malignancies→ 🧪 Hypogammaglobulinaemia→ 💉 Treatment side effects✅ Prognosis→ Highly variable: depends on stage, cytogenetics (esp. TP53), response to treatment→ Many live with CLL for years with minimal impact→ Survival ranges from 42–82% at 5 years, depending on individual factors📚 Use These for MSRA Revision:📝 CLL Revision Noteshttps://www.passthemsra.com/topic/chronic-lymphocytic-leukaemia-revision-notes/🃏 Flashcardshttps://www.passthemsra.com/topic/chronic-lymphocytic-leukaemia-flashcards/📖 Accordion Q&A Noteshttps://www.passthemsra.com/topic/chronic-lymphocytic-leukaemia-accordion-qa-notes/🧠 Rapid Fire Quizhttps://www.passthemsra.com/topic/chronic-lymphocytic-leukaemia-rapid-quiz/🧪 Practice Quizhttps://www.passthemsra.com/quizzes/chronic-lymphocytic-leukaemia/📌 Final Thoughts for Reflection:In slow-growing CLL, the biggest challenge isn’t just the disease — it’s knowing when to start treatment. Balancing risks, side effects, and quality of life is crucial. This deep dive highlights the power of shared decision-making and the need for personalised care in modern haematology. 🩺#MSRA #ChronicLymphocyticLeukaemia #MSRAFlashcards #MSRAQuiz #MSRAQuestionBank #CLL #HaematologyMSRA #WatchfulWaiting #RichtersTransformation #Leukaemia #MedicalRevision #PassTheMSRA